Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc. Warrants
Your view on ERNAW
Overview
What the company does, where it operates, and who runs it.
About Ernexa Therapeutics Inc. Warrants
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sanjeev Luther
- Headquarters
- 1035 Cambridge Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sanjeev Luther
- Headquarters
- 1035 Cambridge Street, Cambridge, MA, US
Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions.
Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this, ERNA-102 is another iMSC designed to deliver the anti-inflammatory cytokine IL-10, targeting rheumatoid arthritis.
Ernexa Therapeutics has secured a licensing agreement with Factor Bioscience Limited. The company, founded in 2018 and headquartered in Cambridge, Massachusetts, was formerly named Eterna Therapeutics Inc., before officially changing to Ernexa Therapeutics in March 2025.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Ernexa Therapeutics Inc. Warrants, and the rating behind it. ERNAW last traded at $0.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Ernexa Therapeutics Inc. Warrants. Starting points for Ernexa Therapeutics Inc. Warrants: EPS -$10.36, beta 2.65 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Ernexa Therapeutics Inc. Warrants. Ernexa Therapeutics Inc. Warrants does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Ernexa Therapeutics Inc. Warrants. Trailing twelve-month EPS for Ernexa Therapeutics Inc. Warrants stands at -$10.36. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Ernexa Therapeutics Inc. Warrants. Ernexa Therapeutics Inc. Warrants has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Ernexa Therapeutics Inc. Warrants valued side by side against its closest peers. Ernexa Therapeutics Inc. Warrants is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Ernexa Therapeutics Inc. Warrants, and how their positions are changing. At a $274,073 market value, institutional positions materially move Ernexa Therapeutics Inc. Warrants's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Ernexa Therapeutics Inc. Warrants executives and directors. Shares of Ernexa Therapeutics Inc. Warrants have traded between $0.04 and $0.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Ernexa Therapeutics Inc. Warrants. Ernexa Therapeutics Inc. Warrants is a $274,073 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Ernexa Therapeutics Inc. Warrants. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Ernexa Therapeutics Inc. Warrants. Coverage tracks Ernexa Therapeutics Inc. Warrants within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.